Related Experiment Video

Updated: Aug 17, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Viral oncolysis

John T Mullen1, Kenneth K Tanabe

  • 1Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2696, USA.

The Oncologist
|April 19, 2002
PubMed

Insights

Genetically engineered oncolytic viruses offer potent, tumor-specific cancer treatment. These viruses leverage viral functions and immune responses to enhance antineoplastic efficacy, with several in clinical trials.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Replicating viruses have long been considered for cancer treatment.
  • Genetic modification has enhanced the potency and tumor specificity of viral vectors.
  • Understanding viral gene functions is key to improving anticancer efficacy.

Purpose of the Study:

  • To review the mechanisms of oncolytic virus antitumor efficacy and specificity.
  • To discuss the dual role of the immune response in oncolytic viral therapy.
  • To examine commonly used oncolytic viruses and their clinical trial status.

Main Methods:

  • Review of general mechanisms of oncolytic virus action.
  • Analysis of viral gene product functions in cell cycle control and defense evasion.
  • Examination of the immune response's paradoxical roles in oncolytic therapy.
  • Review of specific oncolytic viruses: adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, and Newcastle disease viruses.

Main Results:

  • Oncolytic viruses achieve antitumor effects through enhanced viral functions and specificity.
  • The immune system can both hinder viral spread and promote tumor cell destruction.
  • Different oncolytic viruses (adenoviruses, HSV, vaccinia, reoviruses, NDV) possess unique biological properties.
  • Several oncolytic virus mutants are currently undergoing clinical evaluation.

Conclusions:

  • Genetically modified oncolytic viruses represent a promising cancer therapy approach.
  • Optimizing viral functions and understanding immune interactions are crucial for efficacy.
  • Ongoing clinical trials are evaluating the therapeutic potential of various oncolytic viruses.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Viral Replication: Lytic Cycle01:20

Viral Replication: Lytic Cycle

Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...